Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.
A lab study suggests cyclodextrins may help support myelin sheath repair in MS by reducing harmful fat buildup in immune cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results